However, given the high haemorrhage risk evident in MPN patients, especially those with abormal JAK/STAT signalling due to gene mutations, it is important to study more different ways that can direct inhibit JAK/STAT pathway with minimal adverse effect, then can subsequently reduce thrombosis in patients [210]. Here, SOAT1 is linked to myeloproliferative disorder.